Wise Wealth Partners Acquires Shares of 449 Eli Lilly and Company (NYSE:LLY)

Wise Wealth Partners acquired a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 449 shares of the company's stock, valued at approximately $347,000. Eli Lilly and Company accounts for approximately 0.9% of Wise Wealth Partners' investment portfolio, making the stock its 28th largest holding.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Unisphere Establishment boosted its holdings in Eli Lilly and Company by 54.0% in the 4th quarter. Unisphere Establishment now owns 9,700 shares of the company's stock worth $7,488,000 after buying an additional 3,400 shares during the last quarter. Headland Capital LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $228,000. Guardian Capital LP increased its position in shares of Eli Lilly and Company by 6.9% during the fourth quarter. Guardian Capital LP now owns 1,966 shares of the company's stock worth $1,518,000 after purchasing an additional 127 shares in the last quarter. Wick Capital Partners LLC raised its stake in Eli Lilly and Company by 14,364.5% in the 4th quarter. Wick Capital Partners LLC now owns 56,267 shares of the company's stock valued at $43,438,000 after purchasing an additional 55,878 shares during the last quarter. Finally, Navigoe LLC purchased a new position in Eli Lilly and Company in the 4th quarter valued at $77,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 3.9 %

Eli Lilly and Company stock traded up $31.00 during midday trading on Friday, reaching $825.10. 6,056,616 shares of the stock traded hands, compared to its average volume of 3,482,066. The firm has a market cap of $782.34 billion, a PE ratio of 70.46, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company has a 50-day simple moving average of $826.90 and a two-hundred day simple moving average of $816.98. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the previous year, the business posted $2.58 EPS. The company's revenue for the quarter was up 45.2% compared to the same quarter last year. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LLY. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a report on Thursday, January 16th. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a report on Friday, January 17th. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price target for the stock from $1,150.00 to $700.00 in a report on Monday. Finally, UBS Group reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday. One analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,002.80.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.